公开(公告)号：WO2012083138A3

公开(公告)日：2012-11-01

申请号：PCT/US2011065422

申请日：2011-12-16

Applicant: UNIV TEXAS ,  ANDERSSON BORJE S ,  TARRAND JEFFERY ,  VALDEZ BENIGNO C

Inventor： ANDERSSON BORJE S ,  TARRAND JEFFERY ,  VALDEZ BENIGNO C

IPC: A61K47/48 ,  A61K9/10 ,  A61K9/107 ,  A61K31/4164 ,  A61K31/4192 ,  A61K31/4196 ,  A61P31/04

CPC classification number: A61K31/496 ,  A61K9/0019 ,  A61K9/0053 ,  A61K47/10

Abstract: A parenteral azole composition comprises a first solvent, made of benzyl alcohol and/or an acidified alcohol such as ethanol, and a lipophilic component such as PEG400, and the azole, or triazole, such as itraconazole or posaconazole dissolved in this first composite solvent vehicle that is essentially free of surfactants, particularly non-ionic surfactants, and has low levels of water, preferably less than 5% water. The composition may be further diluted with an infusion fluid, such as normal saline or 5% or 10% dextrose in water, before infusion into an immunocompromized mammal, preferably a human. The composition is useful for the treatment and suppression of infections caused by microbes such as yeast and molds that are sensitive to azoles, but it may be extended to dissolve other pharmaceutically active agents that can be used to treat other types of infectious diseases or other ailments, such as malignant and autoimmune diseases.

Abstract translation: 肠胃外唑类组合物包含溶解在该第一复合溶剂载体中的由苯甲醇和/或酸化醇如乙醇制成的第一溶剂和亲脂性组分例如PEG400以及唑或三唑如伊曲康唑或泊沙康唑 其基本上不含表面活性剂，特别是非离子表面活性剂，并且具有低含量的水，优选小于5％的水。 在输注到免疫妥协化的哺乳动物，优选人类中之前，可以用输注流体例如生理盐水或5％或10％葡萄糖水溶液进一步稀释组合物。 该组合物可用于治疗和抑制微生物如对唑类敏感的酵母和霉菌引起的感染，但其可延长用于溶解可用于治疗其他类型的感染性疾病或其他疾病的其它药物活性剂 ，如恶性和自身免疫性疾病。

公开(公告)号：WO2012083138A2

公开(公告)日：2012-06-21

申请号：PCT/US2011/065422

申请日：2011-12-16

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  ANDERSSON, Borje, S. ,  TARRAND, Jeffery ,  VALDEZ, Benigno, C.

Inventor： ANDERSSON, Borje, S. ,  TARRAND, Jeffery ,  VALDEZ, Benigno, C.

IPC: A61K47/48 ,  A61K9/10 ,  A61K9/107 ,  A61K31/4164 ,  A61K31/4192 ,  A61K31/4196 ,  A61P31/04

CPC classification number: A61K31/496 ,  A61K9/0019 ,  A61K9/0053 ,  A61K47/10

Abstract: A parenteral azole composition comprises a first solvent, made of benzyl alcohol and/or an acidified alcohol such as ethanol, and a lipophilic component such as PEG400, and the azole, or triazole, such as itraconazole or posaconazole dissolved in this first composite solvent vehicle that is essentially free of surfactants, particularly non-ionic surfactants, and has low levels of water, preferably less than 5% water. The composition may be further diluted with an infusion fluid, such as normal saline or 5% or 10% dextrose in water, before infusion into an immunocompromized mammal, preferably a human. The composition is useful for the treatment and suppression of infections caused by microbes such as yeast and molds that are sensitive to azoles, but it may be extended to dissolve other pharmaceutically active agents that can be used to treat other types of infectious diseases or other ailments, such as malignant and autoimmune diseases.

Abstract translation: 肠胃外唑类组合物包含由苄醇和/或酸化醇如乙醇制成的第一溶剂和溶于该第一复合溶剂载体中的亲脂性组分如PEG400，唑类或三唑如伊曲康唑或泊沙康唑 其基本上不含表面活性剂，特别是非离子表面活性剂，并且具有低水平的水，优选小于5％的水。 在输注到免疫受损的哺乳动物，优选人中之前，组合物可以用输注液（如生理盐水或5％或10％葡萄糖水溶液）进一步稀释。 该组合物可用于治疗和抑制由诸如对唑类敏感的酵母和霉菌等微生物引起的感染，但可延长其溶解其它可用于治疗其他类型感染性疾病或其它疾病的药物活性剂 ，如恶性和自身免疫性疾病。